BRAF and neoplasm: Not surprisingly, PI3K and Ral pathways are frequently upregulated in melanoma where they participate in the development of acquired drug resistance, frequently undermining BRAF/MEK target therapies in this neoplasia (reviewed in References [71,72,73] and see below).